Ventritex evaluating technologies for atrial tachyarrhythmia treatment.
This article was originally published in The Gray Sheet
Executive Summary
VENTRITEX EYEING ATRIAL TACHYARRHYTHMIA MARKET, company President and CEO Frank Fischer told investors Oct. 17 at the UBS Securities life sciences conference in New York City. The Sunnyvale, California-based manufacturer of implantable cardioverter defibrillators used to treat ventricular tachyarrhythmias is "very interested" in pursuing technologies that could treat atrial tachyarrhythmias, Fisher said. "The very same physician that sees patients with ventricular tachyarrhythmias, most or a good portion of their business is in detecting or treating atrial tachyarrhythmias as well."